294 related articles for article (PubMed ID: 36834806)
21. Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis.
Galluzzo M; Vellucci L; Marcelli L; Paganini C; Bianchi L; Talamonti M
Expert Opin Pharmacother; 2023 Jun; 24(9):981-988. PubMed ID: 37147879
[TBL] [Abstract][Full Text] [Related]
22. English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.
Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Takahashi K; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
J Dermatol; 2023 May; 50(5):e138-e150. PubMed ID: 37132187
[TBL] [Abstract][Full Text] [Related]
23. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
24. Deucravacitinib: First Approval.
Hoy SM
Drugs; 2022 Nov; 82(17):1671-1679. PubMed ID: 36401743
[TBL] [Abstract][Full Text] [Related]
25. Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors.
Zhang K; Ye K; Tang H; Qi Z; Wang T; Mao J; Zhang X; Jiang S
J Med Chem; 2023 Apr; 66(7):4378-4416. PubMed ID: 36951608
[TBL] [Abstract][Full Text] [Related]
26. TYK2: an emerging therapeutic target in rheumatic disease.
Morand E; Merola JF; Tanaka Y; Gladman D; Fleischmann R
Nat Rev Rheumatol; 2024 Apr; 20(4):232-240. PubMed ID: 38467779
[TBL] [Abstract][Full Text] [Related]
27. Discovery of selective TYK2 inhibitors: Design, synthesis, in vitro and in silico studies of promising hits with triazolopyrimidinone scaffold.
Istanbullu H; Coban G; Turunc E; Disel C; Debelec Butuner B
Bioorg Chem; 2024 Jul; 148():107430. PubMed ID: 38728909
[TBL] [Abstract][Full Text] [Related]
28. TYK2 as a novel therapeutic target in psoriasis.
Elyoussfi S; Rane SS; Eyre S; Warren RB
Expert Rev Clin Pharmacol; 2023; 16(6):549-558. PubMed ID: 37287330
[TBL] [Abstract][Full Text] [Related]
29. Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis.
Gooderham MJ; Hong HC; Litvinov IV
Skin Therapy Lett; 2022 Nov; 27(6):1-5. PubMed ID: 36469536
[TBL] [Abstract][Full Text] [Related]
30. Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021).
Gonzalez Lopez de Turiso F; Guckian K
Expert Opin Ther Pat; 2022 Apr; 32(4):365-379. PubMed ID: 35001782
[TBL] [Abstract][Full Text] [Related]
31. Identification of imidazo[1,2-
Moslin R; Gardner D; Santella J; Zhang Y; Duncia JV; Liu C; Lin J; Tokarski JS; Strnad J; Pedicord D; Chen J; Blat Y; Zupa-Fernandez A; Cheng L; Sun H; Chaudhry C; Huang C; D'Arienzo C; Sack JS; Muckelbauer JK; Chang C; Tredup J; Xie D; Aranibar N; Burke JR; Carter PH; Weinstein DS
Medchemcomm; 2017 Apr; 8(4):700-712. PubMed ID: 30108788
[TBL] [Abstract][Full Text] [Related]
32. Identification of
Moslin R; Zhang Y; Wrobleski ST; Lin S; Mertzman M; Spergel S; Tokarski JS; Strnad J; Gillooly K; McIntyre KW; Zupa-Fernandez A; Cheng L; Sun H; Chaudhry C; Huang C; D'Arienzo C; Heimrich E; Yang X; Muckelbauer JK; Chang C; Tredup J; Mulligan D; Xie D; Aranibar N; Chiney M; Burke JR; Lombardo L; Carter PH; Weinstein DS
J Med Chem; 2019 Oct; 62(20):8953-8972. PubMed ID: 31314518
[TBL] [Abstract][Full Text] [Related]
33. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
He X; Chen X; Zhang H; Xie T; Ye XY
Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
[TBL] [Abstract][Full Text] [Related]
34. Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis.
Kingston P; Blauvelt A; Strober B; Armstrong AW
J Psoriasis Psoriatic Arthritis; 2023 Oct; 8(4):156-165. PubMed ID: 38188537
[TBL] [Abstract][Full Text] [Related]
35. Design, Synthesis and Activity Study of Pyridine Derivatives as Highly Effective and Selective TYK2 Inhibitors.
Cheng C; Zhou M; Zhang P; Qian W; Chen L; Chen G
Biomed Res Int; 2022; 2022():6383893. PubMed ID: 35586808
[TBL] [Abstract][Full Text] [Related]
36. TYK2 in Immune Responses and Treatment of Psoriasis.
Shang L; Cao J; Zhao S; Zhang J; He Y
J Inflamm Res; 2022; 15():5373-5385. PubMed ID: 36147687
[TBL] [Abstract][Full Text] [Related]
37. TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases.
Gonciarz M; Pawlak-Buś K; Leszczyński P; Owczarek W
Immunotherapy; 2021 Sep; 13(13):1135-1150. PubMed ID: 34235974
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279.
Leit S; Greenwood J; Carriero S; Mondal S; Abel R; Ashwell M; Blanchette H; Boyles NA; Cartwright M; Collis A; Feng S; Ghanakota P; Harriman GC; Hosagrahara V; Kaila N; Kapeller R; Rafi SB; Romero DL; Tarantino PM; Timaniya J; Toms AV; Wester RT; Westlin W; Srivastava B; Miao W; Tummino P; McElwee JJ; Edmondson SD; Masse CE
J Med Chem; 2023 Aug; 66(15):10473-10496. PubMed ID: 37427891
[TBL] [Abstract][Full Text] [Related]
39. The preclinical discovery and development of deucravacitinib for the treatment of psoriasis.
Coscarella G; Malvaso D; Mannino M; Caldarola G; Fossati B; De Simone C; Chiricozzi A; Peris K
Expert Opin Drug Discov; 2023; 18(11):1201-1208. PubMed ID: 37574849
[TBL] [Abstract][Full Text] [Related]
40. Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling.
Virtanen A; Palmroth M; Liukkonen S; Kurttila A; Haikarainen T; Isomäki P; Silvennoinen O
Arthritis Rheumatol; 2023 Nov; 75(11):2054-2061. PubMed ID: 37134144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]